HLS Therapeutics Inc. offers a portfolio of products that meet and exceed the
stringent quality and safety requirements of the US Food and Drug
Administration and Health Canada. Our primary treatment areas are psychiatric
disorders and cardiovascular risk reduction. Demand for psychiatric treatments is
projected to grow substantially over the next decade due to rising diagnoses,
an aging population, decreased stigmatization of mental health care, and
innovation in pharmaceutical sciences. Similarly, increases in diagnosed
stressors, cardiovascular diseases, and an aging population are expected to
increase the market for effective cardiovascular therapies. Below is an
overview of our therapeutics and their status in the United States and Canada.